Does the media favor ALGS or SPRB?

In the previous week, Aligos Therapeutics and Aligos Therapeutics both had 1 articles in the media. Aligos Therapeutics' average media sentiment score of 1.00 beat Spruce Biosciences' score of 0.00 indicating that Aligos Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aligos Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spruce Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ALGS or TNYA?

In the previous week, Tenaya Therapeutics had 2 more articles in the media than Aligos Therapeutics. MarketBeat recorded 3 mentions for Tenaya Therapeutics and 1 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 1.00 beat Tenaya Therapeutics' score of 0.34 indicating that Aligos Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aligos Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tenaya Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ALGS or CRBU?

In the previous week, Caribou Biosciences had 1 more articles in the media than Aligos Therapeutics. MarketBeat recorded 2 mentions for Caribou Biosciences and 1 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 1.00 beat Caribou Biosciences' score of 0.59 indicating that Aligos Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aligos Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Caribou Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ALGS or ENGN more profitable?

enGene has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -241.01%. enGene's return on equity of -27.97% beat Aligos Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aligos Therapeutics -241.01% -160.72% -92.30% enGene N/A -27.97% -22.65%

Does the media prefer ALGS or ENGN?

In the previous week, enGene had 7 more articles in the media than Aligos Therapeutics. MarketBeat recorded 8 mentions for enGene and 1 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 1.00 beat enGene's score of 0.15 indicating that Aligos Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aligos Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive enGene 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Aligos Therapeutics (ALGS) Competitors

$5.54 +0.04 (+0.73%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$5.70 +0.16 (+2.87%)

As of 10/2/2026 07:30 PM Eastern

Compare

ALGS vs. SPRB, TNYA, CRBU, HURA, and ENGN

Should you buy Aligos Therapeutics stock or one of its competitors? Aligos Therapeutics's main competitors and comparable companies include Spruce Biosciences (SPRB), Tenaya Therapeutics (TNYA), Caribou Biosciences (CRBU), TuHURA Biosciences (HURA), and enGene (ENGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Aligos Therapeutics compare to Spruce Biosciences?

Aligos Therapeutics (NASDAQ:ALGS) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, media sentiment, profitability and risk.

Aligos Therapeutics has a beta of 2.36, suggesting that its stock price is 136% more volatile than the broader market. Comparatively, Spruce Biosciences has a beta of 3.25, suggesting that its stock price is 225% more volatile than the broader market.

Aligos Therapeutics has higher earnings, but lower revenue than Spruce Biosciences. Spruce Biosciences is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$2.19M	15.79	-$24.19M	-$7.30	N/A
Spruce Biosciences	$4.91M	26.72	-$38.97M	-$39.78	N/A

Aligos Therapeutics currently has a consensus price target of $38.50, indicating a potential upside of 594.95%. Spruce Biosciences has a consensus price target of $158.33, indicating a potential upside of 246.39%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Aligos Therapeutics is more favorable than Spruce Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Spruce Biosciences	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

60.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are held by institutional investors. 7.8% of Aligos Therapeutics shares are held by insiders. Comparatively, 4.3% of Spruce Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Spruce Biosciences has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -241.01%. Spruce Biosciences' return on equity of -123.53% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-241.01%	-160.72%	-92.30%
Spruce Biosciences	N/A	-123.53%	-90.35%

In the previous week, Aligos Therapeutics and Aligos Therapeutics both had 1 articles in the media. Aligos Therapeutics' average media sentiment score of 1.00 beat Spruce Biosciences' score of 0.00 indicating that Aligos Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aligos Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spruce Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Aligos Therapeutics and Spruce Biosciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Aligos Therapeutics compare to Tenaya Therapeutics?

Aligos Therapeutics (NASDAQ:ALGS) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends.

Aligos Therapeutics has higher revenue and earnings than Tenaya Therapeutics. Tenaya Therapeutics is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$2.19M	15.79	-$24.19M	-$7.30	N/A
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.53	N/A

Aligos Therapeutics has a beta of 2.36, indicating that its stock price is 136% more volatile than the broader market. Comparatively, Tenaya Therapeutics has a beta of 2.87, indicating that its stock price is 187% more volatile than the broader market.

Aligos Therapeutics presently has a consensus target price of $38.50, indicating a potential upside of 594.95%. Tenaya Therapeutics has a consensus target price of $4.00, indicating a potential upside of 609.09%. Given Tenaya Therapeutics' higher probable upside, analysts plainly believe Tenaya Therapeutics is more favorable than Aligos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Tenaya Therapeutics has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -241.01%. Tenaya Therapeutics' return on equity of -83.75% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-241.01%	-160.72%	-92.30%
Tenaya Therapeutics	N/A	-83.75%	-66.53%

In the previous week, Tenaya Therapeutics had 2 more articles in the media than Aligos Therapeutics. MarketBeat recorded 3 mentions for Tenaya Therapeutics and 1 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 1.00 beat Tenaya Therapeutics' score of 0.34 indicating that Aligos Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aligos Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tenaya Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are owned by institutional investors. 7.8% of Aligos Therapeutics shares are owned by company insiders. Comparatively, 2.5% of Tenaya Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Tenaya Therapeutics beats Aligos Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Aligos Therapeutics compare to Caribou Biosciences?

Aligos Therapeutics (NASDAQ:ALGS) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Aligos Therapeutics has a beta of 2.36, meaning that its stock price is 136% more volatile than the broader market. Comparatively, Caribou Biosciences has a beta of 2.31, meaning that its stock price is 131% more volatile than the broader market.

Aligos Therapeutics currently has a consensus price target of $38.50, suggesting a potential upside of 594.95%. Caribou Biosciences has a consensus price target of $7.75, suggesting a potential upside of 535.25%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Aligos Therapeutics is more favorable than Caribou Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Caribou Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Aligos Therapeutics has higher earnings, but lower revenue than Caribou Biosciences. Caribou Biosciences is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$2.19M	15.79	-$24.19M	-$7.30	N/A
Caribou Biosciences	$11.16M	11.72	-$148.12M	-$1.08	N/A

60.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are held by institutional investors. 7.8% of Aligos Therapeutics shares are held by insiders. Comparatively, 8.5% of Caribou Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Caribou Biosciences had 1 more articles in the media than Aligos Therapeutics. MarketBeat recorded 2 mentions for Caribou Biosciences and 1 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 1.00 beat Caribou Biosciences' score of 0.59 indicating that Aligos Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aligos Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Caribou Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aligos Therapeutics has a net margin of -241.01% compared to Caribou Biosciences' net margin of -1,030.42%. Caribou Biosciences' return on equity of -89.11% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-241.01%	-160.72%	-92.30%
Caribou Biosciences	-1,030.42%	-89.11%	-62.47%

Summary

Aligos Therapeutics beats Caribou Biosciences on 9 of the 16 factors compared between the two stocks.

How does Aligos Therapeutics compare to TuHURA Biosciences?

Aligos Therapeutics (NASDAQ:ALGS) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

TuHURA Biosciences has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -241.01%. TuHURA Biosciences' return on equity of -156.47% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-241.01%	-160.72%	-92.30%
TuHURA Biosciences	N/A	-156.47%	-106.98%

60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are owned by institutional investors. 7.8% of Aligos Therapeutics shares are owned by company insiders. Comparatively, 6.1% of TuHURA Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Aligos Therapeutics has a beta of 2.36, suggesting that its share price is 136% more volatile than the broader market. Comparatively, TuHURA Biosciences has a beta of -0.21, suggesting that its share price is 121% less volatile than the broader market.

Aligos Therapeutics currently has a consensus target price of $38.50, indicating a potential upside of 594.95%. TuHURA Biosciences has a consensus target price of $9.00, indicating a potential upside of 371.20%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Aligos Therapeutics is more favorable than TuHURA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Aligos Therapeutics has higher revenue and earnings than TuHURA Biosciences. TuHURA Biosciences is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$2.19M	15.79	-$24.19M	-$7.30	N/A
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.54	N/A

In the previous week, Aligos Therapeutics had 1 more articles in the media than TuHURA Biosciences. MarketBeat recorded 1 mentions for Aligos Therapeutics and 0 mentions for TuHURA Biosciences. Aligos Therapeutics' average media sentiment score of 1.00 beat TuHURA Biosciences' score of 0.00 indicating that Aligos Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aligos Therapeutics	Positive
TuHURA Biosciences	Neutral

Summary

Aligos Therapeutics beats TuHURA Biosciences on 12 of the 15 factors compared between the two stocks.

How does Aligos Therapeutics compare to enGene?

Aligos Therapeutics (NASDAQ:ALGS) and enGene (NASDAQ:ENGN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Aligos Therapeutics has a beta of 2.36, meaning that its share price is 136% more volatile than the broader market. Comparatively, enGene has a beta of -0.29, meaning that its share price is 129% less volatile than the broader market.

Aligos Therapeutics presently has a consensus target price of $38.50, indicating a potential upside of 594.95%. enGene has a consensus target price of $11.05, indicating a potential upside of 469.35%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Aligos Therapeutics is more favorable than enGene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14

Aligos Therapeutics has higher revenue and earnings than enGene. enGene is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$2.19M	15.79	-$24.19M	-$7.30	N/A
enGene	N/A	N/A	-$117.30M	-$1.13	N/A

In the previous week, enGene had 7 more articles in the media than Aligos Therapeutics. MarketBeat recorded 8 mentions for enGene and 1 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 1.00 beat enGene's score of 0.15 indicating that Aligos Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aligos Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
enGene	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

enGene has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -241.01%. enGene's return on equity of -27.97% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-241.01%	-160.72%	-92.30%
enGene	N/A	-27.97%	-22.65%

60.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 64.2% of enGene shares are held by institutional investors. 7.8% of Aligos Therapeutics shares are held by insiders. Comparatively, 10.5% of enGene shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Aligos Therapeutics beats enGene on 9 of the 16 factors compared between the two stocks.

Get Aligos Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALGS vs. The Competition

Export

Metric	Aligos Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$34.60M	$3.85B	$7.15B	$13.28B
Dividend Yield	N/A	3.65%	2.54%	17.33%
P/E Ratio	-0.76	13.00	274.71	26.04
Price / Sales	15.79	1,288.64	656.46	105.13
Price / Cash	N/A	123.39	78.87	52.62
Price / Book	0.64	16.57	10.93	6.31
Net Income	-$24.19M	-$22.66M	$3.51B	$362.16M
7 Day Performance	0.54%	-2.97%	-2.00%	-1.66%
1 Month Performance	-10.79%	-10.82%	-6.19%	-4.68%
1 Year Performance	-44.99%	19.00%	8.03%	1.57%

Aligos Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALGS Aligos Therapeutics	1.8875 of 5 stars	$5.54 +0.7%	$38.50 +594.9%	-45.0%	$34.60M	$2.19M	N/A	82
SPRB Spruce Biosciences	3.1932 of 5 stars	$47.27 -0.5%	$158.33 +235.0%	+475.0%	$135.67M	$4.91M	N/A	8	Gap Up
TNYA Tenaya Therapeutics	2.4577 of 5 stars	$0.59 +0.6%	$4.00 +574.4%	-65.2%	$132.99M	N/A	N/A	70
CRBU Caribou Biosciences	2.4876 of 5 stars	$1.24 +0.8%	$7.75 +525.0%	-46.3%	$132.94M	$11.16M	N/A	97	News Coverage
HURA TuHURA Biosciences	1.1674 of 5 stars	$2.07 -1.0%	$9.00 +334.8%	-26.5%	$131.92M	N/A	N/A	22	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALGS) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aligos Therapeutics (ALGS) Competitors

ALGS vs. SPRB, TNYA, CRBU, HURA, and ENGN

How does Aligos Therapeutics compare to Spruce Biosciences?

Summary

How does Aligos Therapeutics compare to Tenaya Therapeutics?

Summary

How does Aligos Therapeutics compare to Caribou Biosciences?

Summary

How does Aligos Therapeutics compare to TuHURA Biosciences?

Summary

How does Aligos Therapeutics compare to enGene?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALGS vs. The Competition

Aligos Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aligos Therapeutics (ALGS) Competitors

ALGS vs. SPRB, TNYA, CRBU, HURA, and ENGN

How does Aligos Therapeutics compare to Spruce Biosciences?

Which has more volatility & risk, ALGS or SPRB?

Which has better earnings & valuation, ALGS or SPRB?

Do analysts rate ALGS or SPRB?

Do institutionals and insiders have more ownership in ALGS or SPRB?

Is ALGS or SPRB more profitable?

Does the media favor ALGS or SPRB?

Summary

How does Aligos Therapeutics compare to Tenaya Therapeutics?

Which has better valuation & earnings, ALGS or TNYA?

Which has more risk & volatility, ALGS or TNYA?

Do analysts recommend ALGS or TNYA?

Is ALGS or TNYA more profitable?

Does the media favor ALGS or TNYA?

Do institutionals and insiders believe in ALGS or TNYA?

Summary

How does Aligos Therapeutics compare to Caribou Biosciences?

Which has more risk and volatility, ALGS or CRBU?

Do analysts rate ALGS or CRBU?

Which has preferable valuation and earnings, ALGS or CRBU?

Do institutionals and insiders have more ownership in ALGS or CRBU?

Does the media prefer ALGS or CRBU?

Is ALGS or CRBU more profitable?

Summary

How does Aligos Therapeutics compare to TuHURA Biosciences?

Is ALGS or HURA more profitable?

Do insiders and institutionals have more ownership in ALGS or HURA?

Which has more risk and volatility, ALGS or HURA?

Do analysts rate ALGS or HURA?

Which has stronger earnings and valuation, ALGS or HURA?

Does the media prefer ALGS or HURA?

Summary

How does Aligos Therapeutics compare to enGene?

Which has more risk & volatility, ALGS or ENGN?

Do analysts prefer ALGS or ENGN?

Which has preferable valuation and earnings, ALGS or ENGN?

Does the media prefer ALGS or ENGN?

Is ALGS or ENGN more profitable?

Do institutionals & insiders have more ownership in ALGS or ENGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALGS vs. The Competition

Aligos Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools